Polpharma Biologics gains FDA and EMA review acceptances

Polpharma Biologics has received FDA and EMA acceptance for review of its PB016 vedolizumab biosimilar applications, marking a significant step in making affordable biologic treatments available for ulcerative colitis and Crohn's disease.

This Wire brief sits within Fusion42's coverage of Biotech. Wire is Fusion42's founder-focused intelligence feed: each story is connected to the funds and startups it names — every one with a live profile on Raise or Scout — so founders can follow the capital and the momentum behind the headline rather than just the headline itself. Wire analysis is one of the live surfaces Arthur reasons over.